Elucirem

Phase 3Small molecule

JJohns Hopkins University

Elucirem is one of 5 small molecule programs targeting Brain Glioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain GliomaActive, not recruiting

Brain GliomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Brain Glioma

#DrugCompanyPhaseTrials

Sodium Acetate C11

PPhoenix Molecular Imaging

Phase 3

1 2

Elucirem

JJohns Hopkins University

Phase 3

1 3

Tumor Infiltrating Lymphocytes

EEssen Biotech

Phase 1

1 4

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Phase 1

1 5

Avastin

BBio-Thera Solutions

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Brain Glioma1 trial

Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas

Completed·GGuerbet·Phase 3·NCT06057168·138 enrolled

Contrast Agent1 trial

High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment

Recruiting·JJohns Hopkins University·Phase 4·NCT05954559·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Elucirem. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Elucirem compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Elucirem. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johns Hopkins University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJohns Hopkins University

Elucirem

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Brain Glioma1 trial

Contrast Agent1 trial

References

Drug Info

Quick Facts

Related News